Delayed Prostate Cancer Therapy Centereach NY

The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues.

Local Companies

MICHAEL DOSIK, MD
(631) 751-3000
235 N Belle Mead Road
East Setauket, NY
EMMANUEL SYGACO, MD
(631) 422-4545
435 Montauk Highway
West Islip, NY
Stefan Madajewicz, MD
631-444-8382
T-17 Rm 080 HSC,
Stony Brook, NY
John Worthington Ames, MD
631-376-4047
1000 Montauk Hwy
West Islip, NY
Lisa Cupit, MD
631-444-2059
T-15 Rm 040,
Stony Brook, NY
KENNETH GOLD, MD
(631) 666-6752
24 E Main Street
Bay Shore, NY
JULES COHEN, MD
(631) 638-1000
3 Edmund D Pellegrino Road
Stony Brook, NY
SUDHA MUKHI, MD
(631) 422-4545
435 Montauk Highway
West Islip, NY
John Joseph Butler Jr, MD
1504 Yarrow Cir
Bellport, NY
Anjali Sharma, MD
732-915-7789
208A Beaumont Pl
Coram, NY
Data Provided by:
  

Provided By:

MONDAY, July 27 (HealthDay News) -- Men who delay treatment for their early prostate cancer are not especially anxious about living with the disease, new Dutch research shows.

The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues. The findings are published in the Sept. 1 issue of Cancer.

The researchers surveyed 129 men regarding their levels of depression and anxiety over their treatment decision. More than 80 percent scored favorably low and compared well emotionally with patients who had opted for more aggressive treatment, the study found.

Men who were in poor general health and those with neurotic personalities expressed higher levels of anxiety and distress, suggesting that factors other than cancer may impact a patient's emotional response, the researchers noted.

The study is especially useful in an era when prostate-specific antigen tests and other screening exams are uncovering prostate cancer at increasingly earlier stages. Many physicians practice a "wait-and-see" approach to treatment, saving the more aggressive therapies for when the cancer grows or spreads, according to information in a news release from the American Cancer Society.

Nationally, prostate cancer is one of the most common cancers and is expected to strike more than 190,000 men this year, and result in over 27,000 deaths, according to the American Cancer Society. But thanks to more effective screenings and treatments, while one in six U.S. men will develop prostate cancer during their lifetime, only one in 35 will actually die of the disease. What's more, there are more than 2 million men in the United States who have been diagnosed with prostate cancer at some point and are still alive today, according to the society.

More information

The U.S. National Cancer Institute has more on prostate cancer.

SOURCE: American Cancer Society, news release, July 27, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Drug Combo Proves Powerful Against Lung Cancer Centereach NY
A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.
- Open Prostatectomy Versus Laparoscopic Procedure Centereach NY
- Exercise for Prostate Cancer Centereach NY
- Hormone Therapy for Early Prostate Cancer Centereach NY
- Attack Of The Cancer Fighting Tomatoes Centereach NY
- Hormone Therapy for Prostate Cancer Centereach NY
- Head and Neck Cancer Treatment Centereach NY
- Hormone Therapy for Breast Cancer Centereach NY
- Diagnosis of Prostate Cancer Centereach NY
- Hormone Therapy for Lung Cancer Centereach NY